Form 4: Daxor CMO Jefferies Boosts Stake with Equity Grants

Daxor Corp's Chief Medical Officer, John Jefferies, increased his direct beneficial ownership by 5,941 shares through equity grants on March 20, 2026.

Summary

• John Jefferies, Chief Medical Officer of Daxor Corp (DXR), acquired a total of 5,941 shares of common stock through equity grants.
• On March 20, 2026, 3,656 shares were granted, which are scheduled to vest on March 20, 2029.
• Concurrently, 2,285 shares were granted and vested immediately on March 20, 2026.
• Following these transactions, Jefferies' direct beneficial ownership in Daxor Corp increased to 23,557 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it demonstrates a key executive's increased stake and long-term commitment to the company through equity awards, aligning their interests with shareholders.

Positives

• Chief Medical Officer John Jefferies increased his direct beneficial ownership in Daxor Corp by 5,941 shares, signaling continued alignment with shareholder interests.
• A significant portion of the acquired shares (3,656 shares) are subject to future vesting (March 20, 2029), indicating a long-term commitment from a key executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive equity grants are a common practice across industries to incentivize long-term performance and align management interests with those of shareholders. This particular filing indicates a standard compensation event for a key executive at Daxor Corp.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to higher beneficial ownership.
• Employees: May signal stability and confidence in the company's future from top management.

Next Steps

• The 3,656 shares granted on March 20, 2026, are scheduled to vest on March 20, 2029.

Key Dates

Recommendation

The filing reports a routine equity grant to a Chief Medical Officer, increasing their beneficial ownership. While this indicates executive alignment, it does not present new fundamental information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Daxor Corp, DXR, John Jefferies, Chief Medical Officer, Insider Trading, Equity Grant, Stock Award, Beneficial Ownership, SEC Form 4, Executive Compensation